

4. A compound of any one of claims 1 to 4 for use as a medicament.

5. Use of Aa compound of any one of claims 1 to 4 in the manufacture of a medicament for use in the treatment of a neurodegenerative disorder, wherein the neurodegenerative disorder is selected from the group consisting of Alzheimer's disease, mental retardation; CIAS, attention-deficit/hyperactivity disorder; and age-related cognitive decline, substance-induced psychotic disorder, for example psychosis induced by alcohol, amphetamine, cannabis, cocaine, hallucinogens, inhalants, opioids, or phencyclidine.

~~6. A compound of any one of claims 1 to 4 for the preparation of a medicament for use in the treatment of a disorder selected from the group consisting of Alzheimer's disease, mental retardation; CIAS, attention-deficit/hyperactivity disorder; and age-related cognitive decline, substance-induced psychotic disorder, for example psychosis induced by alcohol, amphetamine, cannabis, cocaine, hallucinogens, inhalants, opioids, or phencyclidine.~~

~~7. A method of treating a subject suffering from a disorder, wherein the neurodegenerative disorder is selected from the group consisting of Alzheimer's disease, mental retardation; CIAS, attention-deficit/hyperactivity disorder; and age-related cognitive decline, substance-induced psychotic disorder, for example psychosis induced by alcohol, amphetamine, cannabis, cocaine, hallucinogens, inhalants, opioids, or phencyclidine.~~

8.6. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 1 to 4, and one or more pharmaceutically acceptable carriers, diluents and excipients.